{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:20:13Z","timestamp":1789237213374,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23H05316"],"award-info":[{"award-number":["23H05316"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24H02670"],"award-info":[{"award-number":["24H02670"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06210"],"award-info":[{"award-number":["23K06210"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25H00282"],"award-info":[{"award-number":["25H00282"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejps.2025.107309","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T01:33:39Z","timestamp":1759628019000},"page":"107309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Esomeprazole prevents oxaliplatin-induced peripheral neuropathy through inhibiting organic cation transporter 2 in mice"],"prefix":"10.1016","volume":"214","author":[{"given":"Manami","family":"Ueno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ikemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Wakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Yamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2025.107309_bib0001","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1159\/000506232","article-title":"Comparison of antioxidant effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole","volume":"105","author":"Abed","year":"2020","journal-title":"Pharmacology"},{"key":"10.1016\/j.ejps.2025.107309_bib0002","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107309_bib0003","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1007\/s12035-018-0920-4","article-title":"Rosmarinic acid mitigates mitochondrial dysfunction and spinal glial activation in oxaliplatin-induced peripheral neuropathy","volume":"55","author":"Areti","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejps.2025.107309_bib0004","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.taap.2017.03.009","article-title":"Carvedilol prevents functional deficits in peripheral nerve mitochondria of rats with oxaliplatin-evoked painful peripheral neuropathy","volume":"322","author":"Areti","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107309_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058837","article-title":"The proton-pump inhibitor lansoprazole enhances amyloid beta production","volume":"8","author":"Badiola","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2025.107309_bib0006","first-page":"427","article-title":"Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life","volume":"32","author":"Balayssac","year":"2024","journal-title":"Support. Care Cancer."},{"key":"10.1016\/j.ejps.2025.107309_bib0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J. Neurosci. Methods."},{"key":"10.1016\/j.ejps.2025.107309_bib0008","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bbrc.2022.04.107","article-title":"The protective effect of rabeprazole on cisplatin-induced apoptosis and necroptosis of renal proximal tubular cells","volume":"612","author":"Chen","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejps.2025.107309_bib0009","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s12664-023-01501-1","article-title":"Trend analysis of proton pump inhibitor consumption and expenditure: the real-world evidence","volume":"43","author":"Ferrara","year":"2024","journal-title":"Ind. J Gastroenterol"},{"key":"10.1016\/j.ejps.2025.107309_bib0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jnc.14607","article-title":"Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy","volume":"148","author":"Fujita","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejps.2025.107309_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer","volume":"25","author":"Hashiguchi","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107309_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.937166","article-title":"Proton pump inhibitors and sensitization of cancer cells to radiation therapy","volume":"12","author":"Hebert","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejps.2025.107309_bib0013","first-page":"342","article-title":"Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model","volume":"46","author":"Holmes","year":"1998","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejps.2025.107309_bib0014","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1172\/JCI136796","article-title":"Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice","volume":"130","author":"Huang","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejps.2025.107309_bib0015","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1124\/dmd.116.070722","article-title":"Lansoprazole exacerbates pemetrexed-mediated hematologic toxicity by competitive inhibition of renal basolateral human organic anion transporter 3","volume":"44","author":"Ikemura","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2025.107309_bib0016","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bph.13698","article-title":"miR-15b mediates oxaliplatin-induced chronic neuropathic pain through BACE1 down-regulation","volume":"174","author":"Ito","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107309_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.aquatox.2023.106573","article-title":"Protective effects of esomeprazole against cisplatin-induced ototoxicity: an in vitro and in vivo study","volume":"260","author":"Jeon","year":"2023","journal-title":"Aquat. Toxicol."},{"key":"10.1016\/j.ejps.2025.107309_bib0018","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1248\/bpb.33.1867","article-title":"Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity","volume":"33","author":"Katsuda","year":"2010","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejps.2025.107309_bib0019","first-page":"1","article-title":"Review article: esomeprazole\u2014the first proton pump inhibitor to be developed as an isomer","volume":"1","author":"Kendall","year":"2003","journal-title":"Aliment. Pharmacol. Ther. 17 Suppl"},{"key":"10.1016\/j.ejps.2025.107309_bib0020","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1021\/jm2001629","article-title":"Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2","volume":"54","author":"Kido","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2025.107309_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118272","article-title":"Lansoprazole identified as a prophylactic agent for oxaliplatin-induced peripheral neuropathy using integrated in silico, in vitro, and in vivo analyses","volume":"189","author":"Kobayashi","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejps.2025.107309_bib0022","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.21873\/anticanres.16764","article-title":"Proton pump inhibitors ameliorate oxaliplatin-induced peripheral neuropathy: retrospective analysis of two real-world clinical databases","volume":"43","author":"Kobayashi","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejps.2025.107309_bib0023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0165-022X(02)00136-7","article-title":"Enantiomeric composition of abused amine drugs: chromatographic methods of analysis and data interpretation","volume":"54","author":"Liu","year":"2002","journal-title":"J. Biochem. Biophys. Methods."},{"key":"10.1016\/j.ejps.2025.107309_bib0024","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2025.107309_bib0025","doi-asserted-by":"crossref","first-page":"8859","DOI":"10.3390\/ijms23168859","article-title":"Omeprazole suppresses oxaliplatin-induced peripheral neuropathy in a rodent model and clinical database","volume":"23","author":"Mine","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2025.107309_bib0026","article-title":"Proton pump inhibitor concomitant use to prevent oxaliplatin-induced peripheral neuropathy: clinical retrospective cohort study","author":"Mine","year":"2025","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejps.2025.107309_bib0027","doi-asserted-by":"crossref","first-page":"85","DOI":"10.59566\/IJBS.2006.2085","article-title":"Chiral drugs: an overview","volume":"2","author":"Nguyen","year":"2006","journal-title":"Int. J. Biomed. Sci."},{"key":"10.1016\/j.ejps.2025.107309_bib0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022163","article-title":"Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)","volume":"6","author":"Nies","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2025.107309_bib0029","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jphs.2019.10.005","article-title":"Improvement of peripheral vascular impairment by a phosphodiesterase type 5 inhibitor tadalafil prevents oxaliplatin-induced peripheral neuropathy in mice","volume":"141","author":"Ogihara","year":"2019","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2025.107309_bib0030","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.bcp.2008.07.005","article-title":"Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1\/hMATE1 and hOCT2\/hMATE1","volume":"76","author":"Sato","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107309_bib0031","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.neuro.2009.01.003","article-title":"Role of MAPKs in platinum-induced neuronal apoptosis","volume":"30","author":"Scuteri","year":"2009","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejps.2025.107309_bib0032","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1021\/mp400403s","article-title":"Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development","volume":"10","author":"Smelick","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2025.107309_bib0033","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1305321110","article-title":"Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2","volume":"110","author":"Sprowl","year":"2013","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejps.2025.107309_bib0034","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.neuro.2006.04.010","article-title":"Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding","volume":"27","author":"Ta","year":"2006","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejps.2025.107309_bib0035","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1572-0241.2007.01106.x","article-title":"The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use","volume":"102","author":"Targownik","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ejps.2025.107309_bib0036","doi-asserted-by":"crossref","first-page":"575","DOI":"10.21873\/anticanres.16846","article-title":"Pharmacokinetic-toxicodynamic Modeling to Elucidate the Involvement of Dorsal Root Ganglion Neuron in Oxaliplatin-induced Peripheral Neuropathy","volume":"44","author":"Tsukushi","year":"2024","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejps.2025.107309_bib0037","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jns.12432","article-title":"Platinum accumulation in oxaliplatin-induced peripheral neuropathy","volume":"26","author":"Wei","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.ejps.2025.107309_bib0038","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/acsbiomaterials.7b00921","article-title":"Platinum (II) complex-nuclear localization sequence peptide hybrid for overcoming platinum resistance in cancer therapy","volume":"4","author":"Wlodarczyk","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.ejps.2025.107309_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270252","article-title":"Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan","volume":"17","author":"Yamamichi","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2025.107309_bib0040","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/pharmaceutics13050698","article-title":"A whole-body physiologically based pharmacokinetic model characterizing interplay of OCTs and MATEs in intestine, liver and kidney to predict drug-drug interactions of metformin with perpetrators","volume":"13","author":"Yang","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejps.2025.107309_bib0041","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s13046-021-02141-z","article-title":"Targeting strategies for oxaliplatin-induced peripheral neuropathy: clinical syndrome, molecular basis, and drug development","volume":"40","author":"Yang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2025.107309_bib0042","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.bcp.2007.03.004","article-title":"Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity","volume":"74","author":"Yokoo","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2025.107309_bib0043","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1124\/jpet.106.110346","article-title":"Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family)","volume":"319","author":"Yonezawa","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2025.107309_bib0044","article-title":"Transcriptional regulation of miR-15b by c-Rel and CREB in Japanese encephalitis virus infection","volume":"6","author":"Zhu","year":"2016","journal-title":"Sci. Rep."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098725003070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:42:00Z","timestamp":1767800520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098725003070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":44,"alternative-id":["S0928098725003070"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107309","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Esomeprazole prevents oxaliplatin-induced peripheral neuropathy through inhibiting organic cation transporter 2 in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107309","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107309"}}